MAPK1 and colitis: Shi and colleagues demonstrated that treatment with N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) played a protective role in experimental colitis and suppressed TNF-α-induced inflammatory responses of IECs by inhibiting the activation of the MEK/ERK signaling pathway [40].